1. The Evaluation of Uterine Sarcomas: Tertiary Center Experience.
- Author
-
YAVUZ, Onur, MANKAN, Kadir Alper, AKDONER, Asli, OT, Sultan, and SAATLI, Hasan Bahadir
- Subjects
UTERINE tumors ,RISK assessment ,CROSS-sectional method ,SARCOMA ,CANCER relapse ,SURVIVAL rate ,RADIOTHERAPY ,DATA analysis ,LEIOMYOSARCOMA ,KRUSKAL-Wallis Test ,FISHER exact test ,ADJUVANT treatment of cancer ,TREATMENT effectiveness ,RETROSPECTIVE studies ,CHI-squared test ,DESCRIPTIVE statistics ,CANCER patients ,CHEMORADIOTHERAPY ,ENDOMETRIAL tumors ,ADJUVANT chemotherapy ,KAPLAN-Meier estimator ,LOG-rank test ,LONGITUDINAL method ,MEDICAL records ,ACQUISITION of data ,STATISTICS ,PROGRESSION-free survival ,COMPARATIVE studies ,DATA analysis software ,OVERALL survival ,DISEASE risk factors - Abstract
OBJECTIVES: To elucidate prognostic factors, determine the best course of treatment methods, and assess oncological results in individuals diagnosed with uterine sarcoma. STUDY DESIGN: Between January 2001 and August 2023, 30 patients with uterine sarcomas (US) were included and analyzed in this cross-sectional study. Sixteen patients (53.3%) had uterine leiomyosarcoma, 6 patients (20%) had high-grade endometrial stromal sarcoma, 8 patients (26.7%) had low-grade endometrial stromal sarcoma. RESULTS: The median follow-up of all participants was 50 months. Recurrence was detected in 43.3% of the patients. 5-year survival ratio was 73.3%, 5-year disease-free survival ratio was 66.7%, the overall survival ratio was 70% and the overall disease-free survival rate was 56.6%. No difference was observed between groups in terms of survival comparisons. No statistically significant effect of adjuvant systemic chemotherapy, adjuvant radiotherapy, and combined treatments on median overall survival and median disease-free survival was detected (p>0.05). CONCLUSION: Uterine sarcomas are uncommon malignancies characterized by a poor prognosis, even in early stages, and they are associated with a high recurrence ratio. The most effective treatment method remains unclear to date. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF